1. Glenn S Tillotson has almost 30 years of pharmaceutical experience, including clinical research, commercialization, medical affairs, strategic drug development, life-cycle management and global launch programs. While at Bayer (Leverkusen, Germany), he was instrumental in the development of ciprofloxacin and moxifloxacin. He has held various Medical Affairs leadership roles in the past decade. He has published over 140 peer-reviewed manuscripts and is on several journal editorial advisory boards.